Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fulvestrant

FDA-approved product (solution, intramuscular), marketed as Cligavyx, Faslodex, Fulvestrant.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Fulvestrant
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • HER2 Positive Breast Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anti-estrogens
FDA pharmacologic class
Estrogen Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fulvestrant in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fulvestrant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

    NCT07287917 · start 2026-01-26

    Registered record
    Registry ID
    NCT07287917
    Conditions
    Melanoma (Skin Cancer); HER2-low Hormone Receptor Positive Breast Cancer
    Interventions
    AMXT 1501 Dicaprate; DFMO; Fulvestrant; Capivasertib; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-01-26
    Completion
    2028-12-29
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma (Skin Cancer); HER2-low Hormone Receptor Positive Breast Cancer
    InterventionAMXT 1501 Dicaprate; DFMO; Fulvestrant; Capivasertib +1 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

    NCT07037199 · start 2025-08-18

    Registered record
    Registry ID
    NCT07037199
    Conditions
    Advanced Breast Cancer
    Interventions
    Trastuzumab rezetecan + CDK4/6 inhibitors + endocrine therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-18
    Completion
    2030-06-30
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer
    InterventionTrastuzumab rezetecan + CDK4/6 inhibitors + endocrine therapy
    PhasePhase 2
    Registry statusRecruiting

  • Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

    NCT06486883 · start 2025-06-30

    Registered record
    Registry ID
    NCT06486883
    Conditions
    Advanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast Carcinoma
    Interventions
    Trastuzumab deruxtecan (T-DXd, DS-8201a); CDK4/6i plus ET
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-06-30
    Completion
    2028-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast Carcinoma
    InterventionTrastuzumab deruxtecan (T-DXd, DS-8201a); CDK4/6i plus ET
    PhasePhase 2
    Registry statusRecruiting

  • Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

    NCT06851442 · start 2025-05-16

    Registered record
    Registry ID
    NCT06851442
    Conditions
    Breast Cancer
    Interventions
    TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2025-05-16
    Completion
    2025-11-20
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionTQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • SNV4818 in Participants With Advanced Solid Tumors

    NCT06736704 · start 2025-02-20

    Registered record
    Registry ID
    NCT06736704
    Conditions
    Advanced Solid Tumors
    Interventions
    SNV4818; Fulvestrant; Palbociclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-02-20
    Completion
    2027-06
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors
    InterventionSNV4818; Fulvestrant; Palbociclib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

    NCT06680921 · start 2024-11-14

    Registered record
    Registry ID
    NCT06680921
    Conditions
    Locally Advanced or Metastatic Breast Cancer
    Interventions
    SIM0270; Everolimus (Afinitor®); Exemestane tablets; Fulvestrant injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-11-14
    Completion
    2028-08-31
    Enrolment
    482

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced or Metastatic Breast Cancer
    InterventionSIM0270; Everolimus (Afinitor®); Exemestane tablets; Fulvestrant injection
    PhasePhase 3
    Registry statusActive not recruiting

  • Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

    NCT05554354 · start 2024-09-13

    Registered record
    Registry ID
    NCT05554354
    Conditions
    Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma
    Interventions
    Binimetinib; Biopsy Procedure; Biospecimen Collection; Bone Scan; Computed Tomography; Echocardiography Test; Fulvestrant; Magnetic Resonance Imaging; Multigated Acquisition Scan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2024-09-13
    Completion
    2025-04-04
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma
    InterventionBinimetinib; Biopsy Procedure; Biospecimen Collection; Bone Scan +5 more
    PhasePhase 2
    Registry statusTerminated

  • Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

    NCT05872347 · start 2023-09-19

    Registered record
    Registry ID
    NCT05872347
    Conditions
    Breast Cancer Brain Metastases
    Interventions
    SPH4336 Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-09-19
    Completion
    2026-12-31
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Brain Metastases
    InterventionSPH4336 Tablets
    PhasePhase 2
    Registry statusRecruiting

  • Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

    NCT05816655 · start 2023-05-31

    Registered record
    Registry ID
    NCT05816655
    Conditions
    Metastatic Breast Cancer
    Interventions
    Fulvestrant plus AI plus ribociclib; AI plus ribociclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-05-31
    Completion
    2029-06-30
    Enrolment
    202

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionFulvestrant plus AI plus ribociclib; AI plus ribociclib
    PhasePhase 2
    Registry statusRecruiting

  • Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

    NCT05735080 · start 2023-03-28

    Registered record
    Registry ID
    NCT05735080
    Conditions
    Breast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Ovarian Cancer; CCNE1 Amplification; Solid Tumor; Advanced Cancer; Metastatic Cancer
    Interventions
    INX-315; Fulvestrant; Abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2023-03-28
    Completion
    2027-09
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast +5 more
    InterventionINX-315; Fulvestrant; Abemaciclib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

    NCT05384119 · start 2023-01-09

    Registered record
    Registry ID
    NCT05384119
    Conditions
    Breast Cancer
    Interventions
    TTI-101; Palbociclib; Aromatase inhibitor (AI); fulvestrant; ribociclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2023-01-09
    Completion
    2024-04-25
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionTTI-101; Palbociclib; Aromatase inhibitor (AI); fulvestrant +1 more
    PhasePhase 1
    Registry statusTerminated

  • Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor

    NCT05536128 · start 2022-12-31

    Registered record
    Registry ID
    NCT05536128
    Conditions
    Advanced Breast Cancer
    Interventions
    Olaparib; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-12-31
    Completion
    2025-12-31
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer
    InterventionOlaparib; Fulvestrant
    PhasePhase 2
    Registry statusRecruiting

  • Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

    NCT05524584 · start 2022-08-31

    Registered record
    Registry ID
    NCT05524584
    Conditions
    Breast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer
    Interventions
    Fulvestrant; Anastrozole; Abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-08-31
    Completion
    2031-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer
    InterventionFulvestrant; Anastrozole; Abemaciclib
    PhasePhase 2
    Registry statusRecruiting

  • An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer

    NCT05186545 · start 2022-07-01

    Registered record
    Registry ID
    NCT05186545
    Conditions
    Breast Cancer; Breast Cancer Female
    Interventions
    surufatinib + fulvestrant + chidamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-07-01
    Completion
    2025-07
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Breast Cancer Female
    Interventionsurufatinib + fulvestrant + chidamide
    PhasePhase 2
    Registry statusUnknown

  • Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

    NCT05328440 · start 2022-05-20

    Registered record
    Registry ID
    NCT05328440
    Conditions
    Breast Neoplasms
    Interventions
    Pyrotinib Maleate; Dalpiciclib Isethionate Tablets; Inetetamab; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-05-20
    Completion
    2026-01-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms
    InterventionPyrotinib Maleate; Dalpiciclib Isethionate Tablets; Inetetamab; Fulvestrant
    PhasePhase 2
    Registry statusUnknown